|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||4.4200 - 4.6900|
|52 Week Range||3.7600 - 7.2000|
|Beta (3Y Monthly)||0.94|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
KushCo Holdings (KSHB) has been growing revenue at a rapid pace, but on the operational side of its business it has faltered in several areas, giving many investors pause as to whether to take a position in the cannabis packaging and branded packaging company.The company is an attractive picks-and-shovel play because it helps marijuana firms comply with the stringent regulations on the packaging side of the business.With the strong demand KushCo's revenue soared to $52 million for all of fiscal 2018, an increase of 177 percent. In the latest quarter it generated sales of $25 million, up 186 percent year-over-year. For all of fiscal 2019, management has guided for sales to double again.It would be expected that KushCo would be considered a terrific growth story, and one that should continue on for years as the cannabis industry should continue to grow for many years. But that's not the case.Where it fumbled the ballThere are three major areas KushCo has failed to deliver on, two of which resulted in it taking a significant hit to its reputation. The two are the accounting debacle that resulted in it having to restate its financials for 2017 and 2018, and its failure to properly prepare for the very visible increase in demand coming from the legalization of recreational pot in Canada, and the trend toward individual states in America to legalize recreational pot as well.The last negative catalyst was its inability to stop the decline in its margin, part of which wasn't its fault, and part of which it was.Concerning the accounting debacle, that was definitely the fault of the company, as it failed to hire a CFO for that sole purpose, instead opting to have it be combined with the office of the COO. This became an issue when the company made acquisitions that weren't properly handled in order to be in compliance with Sarbanes-Oxley. That appears to have been taken care of, but to allow that to happen in the first place doesn't place a positive light on the Board or the management team.While it was a blow to its reputation, it was also something that has to be solved in order to make the company's financials compliant with Sarbanes-Oxley in order to have its shares listed on a major market in the future. This has likely delayed the process.Lack of preparation for growing demandAnother major issue with the company was it not being prepared for the obvious surge in North American cannabis demand. This was part of the problem in Canada, where shortage of packaging was blamed on KushCo. It wasn't the only reason for the embarrassment to the Canadian government, which deserves a portion of the blame as well, but it in fact did play a part in the shortage.Not being ready for the demand onslaught resulted in supply shortages. But it also forced the company to employ more costly means of delivery in order to get the packaging to dispensaries quicker, once it was manufactured. That resulted in further downward pressure on already low margins.With plenty of time to prepare for the obvious coming demand, this is probably the thing that concerns and disappoints me the most. It's baffling as to how the company wouldn't have contingencies in place in case of demand exceeding expectations, including enough inventory to support that demand.When combined with the disaster surrounding the accounting failure, it does make the management look like its over its head.Margin challengesThere are a couple of things related to margins that provide an answer as to why they haven't been able to improve in that area for some time. The one thing out of the company's control are the tariffs; particularly those that have an impact on the vapes it imports from China. It has applied for relief for some of the tariffs, and believes it has a chance of getting some of them taken off.Management also said it's going to pass on at least some of the tariff costs onto its customers. With demand so high at this time, I don't think that will have an adverse impact on its results.The other major part of its low margin was self-inflicted, again, related to having to use more expensive means of delivery in order to meet supply demands. The combination of tariffs and expensive delivery costs may be behind the company, and that means it could reach the approximate 20 percent margin management guides for. Interestingly, that's still less than the 34.8 percent it enjoyed just a year ago.Another expense associated with being unprepared for demand was the need to invest in new facilities to meet demand. These three things resulted in gross profit margin plummeting to 12.8 percent in the quarter, against the 34.8 percent mentioned above.The question going forward is how much of its margin it'll be able to recoup by passing on tariff costs onto customers, lower delivery costs, and presumably much of its investment in additional facilities being largely completed. With growth in the sector having no end in sight at this time, I think the company will still have to invest in additional facilities so it won't repeat what happened this time around.My biggest concern is even if it is able to boost margins to 20 percent, is what happened to the other 14 percent it generated last year. It appears this may be something associated with its business model in relationship to growth. It also looks like scale, which could help the company increase margins above the 20 percent guidance, is probably not enough to return it to past margin performance.ConclusionKushco may look dismal after what I mentioned above, but the reality is it does have some good things going for it, including the long-term revenue growth prospects from the burgeoning cannabis industry.It also has a diverse customer base where it doesn't rely on any one company for over 10 percent of its sales. It serves over 5,000 marijuana companies, providing it with reduced risk when there is some customer churn.Since it has more than 5,000 customers, it points to the fact its product is in compliance with standards in different markets, and is a source of choice for many companies.Of course it must execute on the supply side to meet demand, or it could find itself losing customers in droves if they can't packaging and packaged branding that allows them to generate sales. Hopefully the company is dealing with that issue in a permanent way.On the revenue side, I don't see it slowing down in the near future, as it estimates sales should jump to as high as $243 million by the end of 2020. If it's able to sustainably improve margin, it could result in the company becoming profitable by the end of the year, as management has stated is highly probable.The company is cheap, but there's a reason for that. But if it is able to surprise in any way in the quarters ahead, it could get a significant boost in its share price, and if it executes in a way that convinces investors its performance is sustainable, it could move up quickly in value.Last, management can not afford to make any of the operational mistakes it already has. If it does in any way, the company will struggle to recover in my view. That would almost certainly mean a change in management and the company taking a lot longer to reward shareholders.As the company stands, it may be good for an occasional trade, but taking a position and holding is very risky. KushCo must prove it can execute and deliver on its promises before the market will jump back in.To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. More recent articles from Smarter Analyst: * Village Farms (VFF) Has a Lot Going for It * Hexo Has Difficult Days Ahead, Analyst Says * Square (SQ) Growth Slowing, But Evercore Remains Bullish on the Stock * This Analyst Sticks with His Buy Rating on Aphria (APHA) Stock, But Trims Price Target
Just how high can CBD sales climb? That's the key question facing companies and regulators as cannabis goes mainstream.
Cannabis stocks were mostly lower Monday, as investors digested the first reports from Friday’s regulatory hearing on cannabis and its ingredients and the news that Illinois is legalizing weed for adult recreational use.
Aphria Inc. shares soared about 9% Friday to lead the cannabis sector, after Jefferies started coverage of the stock with a buy rating.
Cannabis Stocks Fell despite Biden's Support of LegalizationA weak startThe overall cannabis sector was off to a weak start this week. The weakness was reflected in the Horizons Marijuana Life Sciences ETF (HMMJ), which sank by nearly 1.4%, and the
The U.S. trade tiff with China even affects the marijuana trade. But ironically, the companies hurt are those that carefully avoid touching the still federally illegal weed itself.
Cannabis Sector Fell on CRON's Earnings and Trade Tensions(Continued from Prior Part)Sector declinesIn the week ending May 10, the overall market sentiment was pessimistic with the TSE Composite Index losing almost 1.2% The ETFMG Alternative Harvest
Cannabis Sector Extended Its Losses Last Week(Continued from Prior Part)Cannabis stocks fellLast week, most of the stocks in the cannabis sector ended lower. The Horizons Marijuana Life Sciences ETF (HMMJ) fell ~1.2%, while the ETFMG Alternative
ACB Trades Sideways ahead of Its Earnings Results(Continued from Prior Part)Sector performanceThe cannabis sector has been trading broadly flat ahead of the first-quarter earnings season. The Horizons Marijuana Life Sciences ETF (HMMJ) was up
Medmen Enterprises Inc (OTC: MMNFF) has licenses for 82 stores in four states — California, Florida, Nevada and New York — Vahan Ajamian, the company's managing director of analyst relations, said in a presentation. Echoing a common theme at the Cannabis Capital Conference, Ajamian said California, where MedMen has 10 stores and is building out two more, is the ultimate prize for the cannabis industry as a retail trendsetter.
CTST, TLRY, CGC, and Other Cannabis Stocks on the Rise(Continued from Prior Part)HEXO and APHA gain Today, HEXO (HEXO) was moving higher with a daily gain of 1.3% around noon while Aphria (APHA) wasn’t far behind with a gain of about 1%. When we
Cannabis Stocks Slump as Broader Market Rises(Continued from Prior Part)Sector weaknessWhile the overall cannabis sector experienced weakness on April 23, as is evident in the declines in benchmark ETFs such as the Horizons Marijuana Life Sciences
Cannabis Stocks Off to a Positive Start on Monday(Continued from Prior Part)Stocks in the green Tilray (TLRY), which has been battered and unperformed peers so far this year, was seeing gains early this morning. The stock rose 1.2% as of noon while
CGC, HEXO, CTST Moving Higher Today(Continued from Prior Part)Tilray mutedOn April 17, Tilray (TLRY) remained muted, with the stock almost flat as of noon. The stock remained depressed as the overall cannabis industry has slumped in April.
Jason Vegotsky went from co-founding a beef jerky company to playing a leadership role in KushCo Holdings, Inc. (OTC: KSHB), a supplier of "something to just about everyone" in the cannabis space, he said Wednesday in a keynote address at the Benzinga Cannabis Conference in Toronto. Vegotsky, KushCo's chief revenue officer, told a packed crowd he recognized the tremendous white space opportunity in the cannabis industry and has helped grow his company to generate $35 million in revenue. The entrepreneurial spirit alone isn't enough, as a company needs C-level executives with tremendous experience in their respective fields, the CRO said. For example, KushCo's chief operating officer helped revamp Nike Inc (NYSE: NKE)'s supply chain, and the company's CFO boasts experience in strategic financing transactions and M&A activities.
Cannabis Sector Was Disappointing Last WeekCannabis sector The week ending April 12 was disappointing for the cannabis sector. Most of the stocks ended the week on a negative note. The sector ETFs were broadly lower last week. For example, the
KushCo Holdings (KSHB) stock climbed nearly 4% in Friday's trading session, after the cannabis packaging solutions provider delivered the goods with its fiscal second-quarter results.The most exciting figure to come out of KushCo's quarterly report was its top-line results. For the quarter, sales were up by 240% from the year-ago quarter to $35.2 million, representing the highest quarterly revenue in history, as well as 39% sequential growth from the fiscal first-quarter. To put this in perspective, the Street has anticipated 2Q revenue of $25.5 million.But there was one figure that stood out as worrisome for investors -- gross margins. While revenues were well above expectations, gross margins (13%) remained challenged relative to year-ago levels (28%).Seaport analyst Brett Hundley believes there's nothing to be concerned about as he reiterates a Buy rating on KSHB with a $10 price target, which implies nearly 75% upside from current levels. (To watch Hundley's track record, click here)Hundley commented, "The pursuit of cash flow and margin gains is critical, but the real opportunity for this company and its shareholders is within the revenue line; make no mistake about it, this is a volume play, in our view. So long as KushCo maintains its market leading position, we expect its top line to drive considerable value for shareholders, ahead. We believe that the company is now starting to see the initial benefits of scale, and we are excited about the forward opportunity as additional markets across North America turn to value-added recreational products, which require more packaging and innovative solutions. Management is upping its FY19 sales expectations to $140MM-$150MM; we are bringing our estimate up to the top end of this view, while also increasing forward revenue estimates for FY20."Northland analyst Paul Penney added, "KSHB reported yet another quarter of healthy SKU / customer cross sell metrics, which tangibly reinforces our confidence in the company’s ability to build upon its existing / core customer base. More specifically, we were extremely impressed with the company’s major customer growth progress, with 12 (up from 7 last quarter) and 20 (up from 12 last quarter) customers producing >$1M and $500K+ of annual / run-rate revenues. This continued growth is yet another tangible validation point in KSHB’s ability to drive true / incremental value within its highly reputable and growing customer base."Where are gross margins heading? "We believe these near-term margin issues remain mostly inconsequential as the company’s primary near-term focus is making huge market share gains, which it has continued to successfully achieve on a quarterly basis. Looking ahead and over a longer term basis however, we believe KSHB will be able to add ~800-1K basis points of incremental GM’s by YE 2020. We believe the underlying drivers of this improved profitability profile will be multi-fold, ranging from discontinued free shipping, contributions from the Koleto division (higher margin segment) and the anticipated weakening effects of tariffs," Penney opined.Bottom line -- Penney reiterates an Outperform rating on KSHB stock with a 12-month price target of $8.75.To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. More recent articles from Smarter Analyst: * Analysts Pound the Table on Pareteum (TEUM) Stock * Amazon (AMZN) Stock Poised for Continued Growth; Here's Why * Qualcomm (QCOM) Stock Is a Buy Despite Huawei Saga, Says Analyst * Adding a New Marijuana Stock to the Watch List
CGC, CRON, and GTBIF Reverse Their Falling Streaks on April 12(Continued from Prior Part)Breaking the losing streak Cannabis stocks have recently experienced weakness amid concerns surrounding a global slowdown and companies missing their earnings